1. Home
  2. CRBP vs CD Comparison

CRBP vs CD Comparison

Compare CRBP & CD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CRBP

Corbus Pharmaceuticals Holdings Inc.

N/A

Current Price

$11.31

Market Cap

190.3M

Sector

Health Care

ML Signal

N/A

CD

Chaince Digital Holdings Inc. Ordinary Shares

N/A

Current Price

$3.04

Market Cap

227.2M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
CRBP
CD
Founded
2009
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
190.3M
227.2M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
CRBP
CD
Price
$11.31
$3.04
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$45.50
N/A
AVG Volume (30 Days)
516.3K
248.2K
Earning Date
05-08-2026
08-31-2023
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,822,272.00
$1,867,068.00
Revenue This Year
N/A
N/A
Revenue Next Year
$116.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
97.62
277.93
52 Week Low
$7.12
$2.10
52 Week High
$20.56
$14.10

Technical Indicators

Market Signals
Indicator
CRBP
CD
Relative Strength Index (RSI) 66.21 44.16
Support Level $7.62 $2.96
Resistance Level $11.64 $3.22
Average True Range (ATR) 0.60 0.46
MACD 0.07 -0.01
Stochastic Oscillator 83.08 8.06

Price Performance

Historical Comparison
CRBP
CD

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About CD Chaince Digital Holdings Inc. Ordinary Shares

Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.

Share on Social Networks: